ExploreWatchlistsPricing
  1. JP-listed companies
  2. PeptiDream Inc.
  3. Financials
  4. Operating income

PeptiDream Inc. (4587)

Market cap
¥157.4B
P/E ratio
Peptidream develops new drugs using its proprietary PDPS platform and creates radiopharmaceuticals for diagnosing and treating cancer and other diseases.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndOperating income (Million JPY)YoY (%)
Dec 31, 2025-5,013-123.74%
Dec 31, 202421,114+211.73%
Dec 31, 20236,773-24.58%
Dec 31, 20228,980+103.26%
Dec 31, 20214,418-36.81%
Dec 31, 20206,991-888.05%
Dec 31, 2019-887-124.78%
Jun 30, 20193,580+22.98%
Jun 30, 20182,911+16.89%
Jun 30, 20172,490-2.26%
Jun 30, 20162,548+83.17%
Jun 30, 20151,391+590.86%
Jun 30, 2014201

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat